Alder BioPharmaceuticals, Inc.
Corporate Headquarters
11804 North Creek Parkway South
Bothell
Washington
98011
United States
Tel: 425-205-2900
Fax: 425-205-2901
Website: http://www.alderbio.com/
Email: hr@alderbio.com
About Alder BioPharmaceuticals, Inc.
Alder BioPharmaceuticals is a clinical-stage biopharmaceutical company focused on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Alder’s lead product candidate, eptinezumab, is a monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP) and is currently in late-stage clinical development for the prevention of migraine. Unlike other CGRP inhibitors, eptinezumab was specifically designed as an infusion therapy to address significant patient need. Alder is also developing ALD1910, a preclinical mAb that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38) for migraine prevention.
Stock Symbol: ALDR
Stock Exchange: NASDAQ
119 articles with Alder BioPharmaceuticals, Inc.
-
BioSpace takes a look at some of the investigational products that could, one day, provide relief for migraine sufferers.
-
The U.S. Food and Drug Administration has a busy week planned for drug review. Here’s a look at this week’s schedule.
-
Clinical Catch-Up: October 7-11
10/14/2019
It was a busy week for clinical trial announcements. Here’s a look. -
Lundbeck and Alder BioPharmaceuticals announce updated information in the tender offer materials filed with SEC
10/11/2019
H. Lundbeck A/S (Lundbeck) and Alder BioPharmaceuticals (NASDAQ: ALDR) (Alder) each filed updated tender offer materials with the U.S. Securities and Exchange Commission (SEC) in connection with Lundbeck's pending tender offer (the Offer)
-
Alder BioPharmaceuticals® Announces First-in-Human Dosing in Phase 1 ALD1910 Study for Preventive Treatment of MigraineALD1910 is Alder’s first clinical candidate designed to inhibit pituitary adenylate cyclase-activating polypeptide (PACAP)
10/10/2019
Alder BioPharmaceuticals, Inc. announced dosing of the first patient in a Phase 1 clinical study to evaluate ALD1910 as a preventive treatment for migraine.
-
Alder (ALDR) Alert: Johnson Fistel Investigates Proposed Sale of Alder BioPharmaceuticals, Inc.; Are Shareholders Getting a Fair Deal?
9/16/2019
Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR) ("Alder") breached their fiduciary duties in connection with the proposed sale of the Company to Danish pharmaceutical company Lundbeck.
-
Lundbeck announced the acquisition aimed at eptinezumab, Alder’s investigational monoclonal antibody (mAb) for migraine prevention targeting the calcitonin gene-related peptide that has been submitted to the U.S. Food and Drug Administration for potential approval.
-
Alder BioPharmaceuticals® Presents New Data on Migraine-Free Months, Migraine Severity and Quality of Life, Demonstrating Eptinezumab’s Clinical Profile for Migraine Prevention
7/11/2019
Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced new data from post-hoc analyses of its PROMISE-1 and PROMISE-2 Phase 3 clinical trials for eptinezumab, an investigational monoclonal antibody developed for the prevention of migraine
-
Interview: With Less Than One Year Under His Belt, Alder CEO Eyes Becoming a Commercial Company
4/10/2019
Since taking over the role of chief executive officer at Bothell, Wash.-based Alder BioPharmaceuticals in June 2018, Robert Azelby has maintained his focus on moving the company closer to launching its first commercial product in the migraine treatment space. -
Alder BioPharmaceuticals® Submits Biologics License Application to the U.S. Food and Drug Administration for Eptinezumab
2/22/2019
Significant milestone toward the commercialization of eptinezumab, the first quarterly infusion therapy for migraine prevention
-
BioSpace Movers and Shakers for Oct. 15
10/15/2018
Who mixed things up in the biotech world this past week? Pfizer announces its leadership team, Rheos gets a new COO, and board of directors updates from multiple biopharma companies. -
In May the U.S. Food and Drug Administration approved Amgen’s preventative migraine treatment Aimovig. Amgen and its developmental partner Novartis, said the medication would be ready within one week for patients.
-
Alder BioPharmaceuticals® Presents New Six-Month Data for Eptinezumab Demonstrating Improvement in Efficacy in PROMISE 2 Phase 3 Trial for Chronic Migraine
6/29/2018
Data presented today at the American Headache Society (AHS) Annual Scientific Meeting demonstrate 43% of patients receiving 300 mg of eptinezumab achieved a 75% or greater reduction of monthly migraine days
-
Alder BioPharmaceuticals® Presents New One-Year Data for Eptinezumab from PROMISE 1 Phase 3 Trial Demonstrating Long-Term Efficacy in Episodic Migraine
6/29/2018
Data presented today at the American Headache Society (AHS) Annual Scientific Meeting demonstrate eptinezumab’s robust efficacy is further improved at one year following third and fourth quarterly infusions
-
Alder BioPharmaceuticals® to Present New Data Further Highlighting Eptinezumab’s Efficacy Profile for Migraine Prevention at American Headache Society Meeting
6/20/2018
Alder BioPharmaceuticals, Inc. announced that it will present updated data from the PROMISE 1 and PROMISE 2 phase 3 clinical trials for eptinezumab, Alder's lead investigational product candidate for migraine prevention, at the upcoming American Headache Society (AHS) annual scientific meeting
-
FDA Approves Amgen and Novartis Migraine Drug Aimovig, Expected to Be Ready for Patients in 1 Week
5/18/2018
Amgen and Novartis scored a big win in the migraine market late Thursday when the U.S. Food and Drug Administration approved Aimovig (erenumab-aooe) for the preventive treatment of migraine in adults. -
There are a few upcoming approval dates for several companies this week. Let’s take a look at the companies and their products awaiting approval.
-
This year’s American Academy of Neurology meeting in Los Angeles has revealed positive news that can benefit patients across a wide variety of indications.
-
Amgen announced final data from its Phase IIIb LIBERTY clinical trial of Aimovig (erenumab), with positive results likely to lead to a blockbuster drug for migraine sufferers.
-
Biohaven Pharmaceutical released positive top-line results from two Phase III clinical trials of rimegepant for migraine. Despite the positive data, shares were down more than 30 percent in early trading this morning.